Form 4: Neurocrine Biosciences Executive Eric Benevich Exercises Options and Sells Shares
SEC Form 4 Filing
Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences, exercised stock options and sold shares on April 15, 2024, according to a Form 4 filing with the SEC.
Summary
- On April 15, 2024, Eric Benevich, the Chief Commercial Officer of Neurocrine Biosciences, exercised non-qualified stock options to acquire 7,231 shares at $81.49 and 12,587 shares at $81.05.
- He then sold 7,231 shares and 12,587 shares at a weighted average price of $133.3646 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2023.
- Following these transactions, Benevich directly owns 40,778 shares of Neurocrine Biosciences common stock.
- He also holds 26,292 non-qualified stock options with an exercise price of $81.49.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without being accused of trading on non-public information.
Comparison to Industry Standards
- Executive compensation packages in the biotechnology industry often include stock options as a significant component.
- The vesting schedules and exercise prices of these options are generally aligned with industry norms to incentivize long-term performance.
- The use of Rule 10b5-1 trading plans is a standard practice among executives to manage their stock holdings while avoiding potential insider trading concerns.
- Comparing Benevich's transactions to those of executives at similar-sized biotech companies (e.g., BioMarin, Incyte) could provide a benchmark for assessing the magnitude and frequency of his stock sales.
Stakeholder Impact
- The transactions may have a minor impact on shareholders, as the sale of shares by an executive can sometimes be interpreted as a lack of confidence in the company, although the use of a 10b5-1 plan mitigates this concern.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2018-02-05 | Date of grant for non-qualified stock option that vested in 48 equal monthly installments beginning March 5, 2018 and expires on February 5, 2028. |
| 2019-02-07 | Date of grant for non-qualified stock option that vested in 48 equal monthly installments beginning March 7, 2019 and expires on February 7, 2029. |
| 2023-11-29 | Date Eric Benevich adopted a Rule 10b5-1 trading plan. |
| 2024-04-15 | Date of the reported transactions: exercising stock options and selling shares. |
| 2024-04-17 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.